New hope for rare lymphoma: personalized combo therapy trial launches
NCT ID NCT07380984
Summary
This study is testing a personalized treatment approach for adults with early-stage NK/T-cell lymphoma, a rare cancer often linked to Epstein-Barr virus. It combines a type of immunotherapy (a PD-1 antibody) with radiation, aiming to improve survival rates while reducing treatment side effects. The trial is enrolling 47 previously untreated patients to see if this tailored strategy provides better long-term control of the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NATURAL KILLER/T-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ruijin Hospital, Shanghai JiaoTong University School of Medicine
RECRUITINGShanghai, China
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.